EGFR and rectal cancer: Specifically, ST6GAL1 can mediate resistance to chemoradiation in rectal cancer [73], the sensitivity of gastric cancer cells to trastuzumab [72], and resistance to the EGFR inhibitor, gefitinib, in ovarian cancer [100].